Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections

International Journal of Infectious Diseases

Volumn 12, Issue 1, 2008, Pages 16-21

  Baran, Gülseren ^a   Erbay, Ayse ^a   Bodur, Hürrem ^a   Öngürü, Pinar ^a   Akinci, Esragül ^a   Balaban, Neriman ^a   Çevik, Mustafa A ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acinetobacter baumannii; Imipenem resistance; Nosocomial infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; NETILMICIN; PEFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TICARCILLIN; TIMENTIN;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; ENDOTRACHEAL TUBE; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NASOGASTRIC TUBE; NONHUMAN; PROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL INFECTION; SURGICAL PATIENT; TURKEY (REPUBLIC); URINARY CATHETER; URINARY TRACT INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS, TEACHING; HUMANS; IMIPENEM; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SENTINEL SURVEILLANCE; TURKEY;

EID: 37549039107     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.03.005     Document Type: Article

References (23)

1. Cisneros J.M., and Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 8 (2002) 687-693
2. Cisneros J.M., Rodriguez-Bano J., Fernandez-Cuenca F., Ribera A., Vila J., Pascual A., et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 11 (2005) 874-879
3. del Mar Tomas M., Cartelle M., Pertega S., Beceiro A., Llinares P., Canle D., et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11 (2005) 540-546
4. Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., and Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31 (2000) 101-106
5. Corbella X., Montero A., Pujol M., Dominguez M.A., Ayats J., Argerich M.J., et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38 (2000) 4086-4095
6. Fierobe L., Lucet J.C., Decré D., Muller-Serieys C., Deleuze A., Joly-Guillou M.L., et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 22 (2001) 35-40
7. Afzal-Shah M., and Livermore D.M. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 41 (1998) 576-577
8. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988) 128-140
9. Horan T.C., Gaynes R.P., Martone W.J., Jarvis W.R., and Emori T.G. CDC definitions of nosocomial surgical site infection, 1992: a modification of CDC definition of surgical wound infections. Infect Control Hosp Epidemiol 13 (1992) 606-608
10. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., and Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 32 (2001) S104-S113
11. Karlowski J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., and Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001. J Clin Microbiol 47 (2003) 1681-1688
12. Turner P.J., Greenhalgh J.M., and MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 9 (2003) 563-567
13. Lee S.O., Kim N.J., Choi S.H., Hyong Kim T., Chung J.W., Woo J.H., et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 48 (2004) 224-228
14. Joly-Guillou M.L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 11 (2005) 868-873
15. Akinci E., Colpan A., Bodur H., Balaban N., and Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J Hosp Infect 59 (2005) 317-323
16. Scerpella E.G., Wanger A.R., Armitige L., Anderlini P., and Ericsson C.D. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol 16 (1995) 92-97
17. Smolyakov R., Borer A., Riesenberg K., Schlaeffer F., Alkan M., Porath A., et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 54 (2003) 32-38
18. Paton R.H., Miles R.S., Hood J., and Amyes S.G. ARI-1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2 (1993) 81-88
19. Lyytikainen O., Koljalg S., Harma M., and Vuopio-Varkila J. Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. J Hosp Infect 31 (1995) 41-54
20. Seifert H., Baginski R., Schulze A., and Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 37 (1993) 750-753
21. Vila J., Marcos A., Marco F., Abdalla S., Vergara Y., Reig R., et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 37 (1993) 138-141
22. Petrosillo N., Chinello P., Proietti M.F., Cecchini L., Masala M., Franchi C., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005) 682-683
23. Levin A.S. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 8 (2002) 144-153